NDAPERIARTICULARSOLUTION, EXTENDED RELEASEPriority Review
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
ZYNRELEF KIT (bupivacaine and meloxicam) by Heron Therapeutics is cyclooxygenase inhibitors [moa]. First approved in 2021.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYNRELEF KIT is a fixed-dose combination of bupivacaine (local anesthetic) and meloxicam (NSAID) delivered as an extended-release periarticular solution. It is indicated for infiltration into the surgical site to provide prolonged analgesia and reduce inflammation following orthopedic procedures. The formulation works by combining local anesthetic blockade with cyclooxygenase inhibition to extend pain relief beyond the typical duration of standard local anesthetics.
Peak9.6 years to LOE
Product is in peak commercial phase with strong patent protection extending to 2035–2036, suggesting sustained revenue opportunity and stable team sizing for the mid-term.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZYNRELEF represents a specialized orthopedic/surgical pain management opportunity with a niche but growing market segment. Professionals joining this brand will work on differentiated product positioning, surgeon and hospital stakeholder engagement, and protecting market share in a relatively uncrowded competitive space.
Brand Manager
Worked on ZYNRELEF KIT at Heron Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.